Zenas BioPharma, Inc. (ZBIO): A Bull Case Theory

We came crossed a bullish thesis connected Zenas BioPharma, Inc. connected Danny’s Substack by Danny Green. In this article, we volition summarize the bulls’ thesis on ZBIO. Zenas BioPharma, Inc.'s share was trading astatine $27.02 as of February 19th. ZBIO’s trailing P/E was 1.93 according to Yahoo Finance.

Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages successful the improvement and commercialization of transformative immunology-based therapies. ZBIO is transitioning from a pre-revenue signifier to commercialization, with analysts projecting revenues to emergence from adjacent zero to $30 cardinal successful 2026 and important maturation thereafter. Its pb asset, obexelimab, targets IgG4-Related Disease (IgG4-RD), a marketplace with nary approved therapies, offering a uncommon at-home attraction enactment that avoids B-cell depletion and reduces corruption risk.

This unsocial mechanics via CD19/FcγRIIb preserves patients’ immune systems and represents a imaginable competitory moat, though January 2026 proceedings information indicated efficacy whitethorn autumn abbreviated of “best-in-class” expectations, highlighting the binary quality of regulatory and commercialized success. Beyond IgG4-RD, obexelimab is being tested successful Warm Autoimmune Hemolytic Anemia and Multiple Sclerosis, positioning Zenas for a semipermanent relation successful B-cell-mediated autoimmune diseases. CEO Lonnie Moulder, laminitis of TESARO, has cultivated a civilization of “Capital Efficient Innovation,” though accelerated maturation and caller banal volatility, including a 50% driblet successful January 2026, airs risks to endowment retention.

Zenas entered 2026 with ~$270 cardinal successful cash, supporting operations done 2028, and has expanded its pipeline via in-licensing strategies, mitigating early-stage find risk. While aboriginal commercialization volition incur precocious marginal costs, the imaginable merchantability of obexelimab astatine standard offers highly asymmetric upside, peculiarly if the cause becomes the planetary modular of attraction oregon validates its multi-indication potential.

Current marketplace absorption connected hazard ratio metrics underestimates semipermanent value, leaving ZBIO trading astatine a important discount to potential. With flawless execution connected regulatory filings and commercialization, Zenas could execute a marketplace capitalization up to 5 times its existent value, making it an attractive, high-risk, high-reward concern opportunity.

Previously, we covered a bullish thesis on CRISPR Therapeutics AG CRSP by MADD-Scientis successful March 2025, which highlighted Casgevy’s commercialized potential, concern with Vertex, and a broader gene-editing pipeline. CRSP’s banal terms has appreciated by astir 33.65% since our coverage. Danny Green shares a akin presumption but emphasizes Zenas BioPharma ZBIO’s pre-revenue to commercialization modulation and obexelimab’s imaginable successful IgG4-RD and different autoimmune diseases.